Literature DB >> 8690832

Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study.

D Robinson1, M G Woerner, S Pollack, G Lerner.   

Abstract

To evaluate subject selection biases in clinical trials, demographic characteristics (gender, race, and age) of subjects at different phases of evaluation for a multicenter maintenance trial in schizophrenia were examined. Six thousand twelve diagnostically appropriate subjects were screened for the study; of these, 1,320 met eligibility criteria and 528 (9% of the screened sample) entered the study. Women, blacks, and older subjects were more likely not to meet eligibility criteria; women and older subjects were more likely and blacks were less likely to refuse study participation. Overall, compared with the screened population, the sample of subjects who entered the study contained proportionately fewer women (33 vs. 43%), more blacks (48.5 vs. 41%), and fewer older subjects (mean age of the entered sample was 29.4 +/- 7.4 vs. 34.8 +/- 11.3 years for the screened population). Having identified these selection factors, a second goal was to assess the potential clinical relevance of selection biases of these magnitudes on clinical trials using models of hypothetical studies with different degrees of selection bias. These showed that selection biases would rarely change overall study outcomes to a clinically relevant degree. However, in our models, selection biases did limit the ability to make inferences about results for select small subgroups of the study population. Investigators should consider collecting data on the recruitment process to allow estimation of the effects of selection biases on the generalizability of their findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690832     DOI: 10.1097/00004714-199604000-00009

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  16 in total

1.  Effectiveness as an outcome measure for treatment trials in psychiatry.

Authors:  W Wolfgang Fleischhacker; Guy M Goodwin
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

2.  Eligibility, recruitment, and retention of African Americans with severe mental illness in community research.

Authors:  Michelle DeCoux Hampton; Mary C White; Linda Chafetz
Journal:  Community Ment Health J       Date:  2008-11-11

3.  Veteran subjects willingness to participate in schizophrenia clinical trials.

Authors:  J C Hoblyn; R A Rosenheck; S Leatherman; L Weil; Robert Lew
Journal:  Psychiatr Q       Date:  2013-06

4.  Participation bias among suicidal adults in a randomized controlled trial.

Authors:  Shannon Wiltsey Stirman; Gregory K Brown; Marjan Ghahramanlou-Holloway; Allison J Fox; Mariam Zahid Chohan; Aaron T Beck
Journal:  Suicide Life Threat Behav       Date:  2011-02-02

5.  A comparison of neurocognition and functioning in first episode psychosis populations: do research samples reflect the real world?

Authors:  Emily Kline; Victoria Hendel; Michelle Friedman-Yakoobian; Raquelle I Mesholam-Gately; Ann Findeisen; Suzanna Zimmet; Joanne D Wojcik; Tracey L Petryshen; Tsung-Ung W Woo; Jill M Goldstein; Martha E Shenton; Matcheri S Keshavan; Robert W McCarley; Larry J Seidman
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-11-28       Impact factor: 4.328

6.  Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.

Authors:  Erik Johnsen; Rune A Kroken; Tore Wentzel-Larsen; Hugo A Jørgensen
Journal:  BMC Psychiatry       Date:  2010-03-24       Impact factor: 3.630

7.  Comparison of clozapine response for inpatients in the research setting versus routine clinical practice.

Authors:  Douglas L Boggs; Deanna L Kelly; Raymond C Love; Robert P McMahon; Robert R Conley
Journal:  Psychiatr Q       Date:  2008-01-24

Review 8.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

9.  How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?

Authors:  M Riedel; M Strassnig; N Müller; P Zwack; H-J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

Review 10.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.